Community Hydroxychloroquine and Chloroquine Monitoring Service - Bradford District and Craven Health and Care Partnership

CPV: Health services

Procedure method

Award procedure without prior publication of a call for competition

Legal basis

CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)

Procurement category

Services

Notice status

Awarded without competition

Procurement threshold

Unspecified in notice

Regulatory regime

Standard

Commercial structure

Stand-alone contract (no framework)

Competition type

Direct award (no call for competition)

GPA / WTO covered

Yes (GPA)

Recurring procurement

Unspecified in notice

First published

18 Jul 2023, 11:27 BST

Last source update

18 Jul 2023, 11:27 BST

FTS notice number

2023/S 000-020615

Classification (CPV)

Health services

Delivery area

Yorkshire & Humber (UKE)

Official registry OCID

ocds-h6vhtk-03e2e5 Find a Tender

Why no open competition

The procurement falls outside the scope of application of the directive

Published justification

Routine monitoring of patients on Hydroxychloroquine (HCQ) is as per the guidelines and recommendations of the Royal College of Ophthalmologists (Hydroxychloroquine Retinopathy Monitoring Guideline), however currently there is no service provision with BD&C HCP.

We have worked with a community provider, Shipley Ophthalmic Assessment Programme (SOAP), to create a monitoring provision to bridge this gap.

HCQ is a medicine that is effective in treating various long-term inflammatory disorders of the joints and skin (usually prescribed in rheumatology/dermatology). In general, it is a safe and cost-effective medication, particularly when compared to newer anti-inflammatory medicines which can more significant adverse effects on the body. However, some patients taking hydroxychloroquine, or a similar medication called chloroquine, can suffer permanent loss of vision due to retinopathy.

As a result of this, once prescribed the guidelines recommend that a baseline is taken of a patient’s eye health, and dependent upon some other factors, once a patient has been on this drug for 5 years they should begin routine annual monitoring to ensure that the retina is maintaining health.

The monitoring of these patients has not been undertaken in BD&C HCP, with Hospital Eye Services (HES) unable to take on the burden of these patients from either a capacity (HES services were and are already overflowing), or capability (lack of further clinic space).

WY colleagues are now raising the risk index on this matter as they now believe we have patients who have been unmonitored on HCQ for 7 years or slightly greater (2 years beyond the guidelines for routine monitoring), although they are working with Meds Mgt teams to accurately identify the specific cohort and the number of patients involved.

Justification under which formal quotation/tendering process is to be waived:

(g) where specialist expertise/service/works/goods are required, and these are

available from only one source (specialised service).

• The Saltaire & Windhill Medical PartnershipAwarded supplier Cliffe Avenue, Shipley, Yorkshire & Humber, BD17 6NX

No document links were published on the notice.